CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 10

Some of the metrics are blocked by your
consent settings
Refractory systemic juvenile idiopathic arthritis successfully treated with rapamycin
(2021)
Sara Concha
;
Emma Rey-Jurado
;
M Cecilia Poli
;
Rodrigo Hoyos-Bachiloglu
;
Arturo Borzutzky
Scopus© Citations 6 1
Some of the metrics are blocked by your
consent settings
A case report of granuloma faciale, an uncommon cutaneous vasculitis
(2019)
Javier Arellano
;
Pablo Vargas
;
Constanza Pulgar
;
Gabriel Neely
;
Yamile Corredoira
1
Some of the metrics are blocked by your
consent settings
Definition of Uveitis Refractory to Treatment: A Systematic Review in the Absence of a Consensus
(2020)
Rodrigo A. Valenzuela
;
Iván Flores
;
Myriam Pujol
;
Carolina Llanos
;
Ester Carreño
3Scopus© Citations 10
Some of the metrics are blocked by your
consent settings
Frequency and severity of periodontitis among patients with rheumatoid arthritis
(2015)
Sebastián Ibáñez V
;
Cristina Ferreiro
;
Andrés Contreras
;
Omar Valenzuela L
;
Nicolás Giadalah
29 1Scopus© Citations 7
Some of the metrics are blocked by your
consent settings
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study
(2016)
CRISTIAN HUMBERTO LABARCA SOLAR
;
Matthew J. Koster
;
Cynthia S. Crowson
;
Ashima Makol
;
Steven R. Ytterberg
4Scopus© Citations 147
Some of the metrics are blocked by your
consent settings
Sepsis progression to multiple organ dysfunction in carotid chemo/baro-denervated rats treated with lipopolysaccharide
(2015)
Gino Nardocci
;
Aldo Martin
;
Sebastián Abarzúa
;
Jorge Rodríguez
;
Felipe Simon
1Scopus© Citations 27 1
Some of the metrics are blocked by your
consent settings
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study
(2019)
Matthew J. Koster
;
Karthik Yeruva
;
Cynthia S. Crowson
;
Francesco Muratore
;
Cristian Labarca
<jats:sec><jats:title>Objective.</jats:title><jats:p>To determine the effect of methotrexate (MTX) on relapse risk and glucocorticoid (GC) use in a large single-institution cohort of patients with giant cell arteritis (GCA).</jats:p></jats:sec><jats:sec><jats:title>Methods.</jats:title><jats:p>Patients diagnosed with GCA from 1998 to 2013 with confirmed evidence of temporal artery biopsy and/or radiographic evidence of large vessel vasculitis were identified. Each patient with GCA treated with adjunct MTX (case) was matched to a similar patient with GCA treated only with GC (control). GC requirements and relapse events before and after MTX initiation (or corresponding index date) were compared using rate ratios (RR).</jats:p></jats:sec><jats:sec><jats:title>Results.</jats:title><jats:p>Eighty-three cases and 83 controls were identified and compared. No significant differences in age, demographics, laboratory variables, baseline disease characteristics, or mean initial prednisone doses were observed. Median [interquartile range (IQR)] time from GCA diagnosis to MTX initiation in cases was 39 (13–80) weeks and the median (IQR) starting dose was 13.5 (10–15) mg/week. RR comparing relapse rates before and after MTX initiation/index date were significantly reduced in both cases (RR 0.32, 95% CI 0.24–0.41) and controls (RR 0.60, 95% CI 0.43–0.86). The decrease in relapse rate was significantly greater in patients taking MTX than in those taking GC alone (p = 0.004). Rates of GC discontinuation did not differ between groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion.</jats:title><jats:p>In this large single-institution cohort, the addition of MTX to GC decreased the rate of subsequent relapse by nearly 2-fold compared to patients taking GC alone. MTX may be considered as adjunct therapy in patients with GCA to decrease the risk of further relapse events.</jats:p></jats:sec>
Scopus© Citations 44 1
Some of the metrics are blocked by your
consent settings
Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort
(2019)
V R Pimentel-Quiroz
;
M F Ugarte-Gil
;
GB Harvey
;
D Wojdyla
;
G J Pons-Estel
<jats:sec><jats:title>Aim</jats:title><jats:p> The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE). </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20–37) years and 47.8 (17.9–68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48–0.99; p = 0.0440) was protective, while doses of prednisone >15 and ≤60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69–10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35–16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10–2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01–1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11–1.34; p < 0.0001) were predictive factors of serious infections. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients. </jats:p></jats:sec>
6Scopus© Citations 75
Some of the metrics are blocked by your
consent settings
Reversed halo sign as an unusual manifestation of cryptogenic organized pneumonia. Report of one case
(2019)
SCHIAPPACASSE, GIANCARLO
;
Arturo Acevedo
;
René Martínez
;
Jorge Escobar
;
Antonio Hernández
5Scopus© Citations 1
Some of the metrics are blocked by your
consent settings
Glucocorticoid Receptor-alpha and MKP-1 as Candidate Biomarkers for Treatment Response and Disease Activity in Vogt-Koyanagi-Harada Disease
(2019)
Cristhian A. Urzua
;
Ping Chen
;
Benjamin Chaigne-Delalande
;
Baoying Liu
;
Rodrigo Anguita
42Scopus© Citations 5

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results